Fig. 5
From: Identification of GRIN2D as a novel therapeutic target in pancreatic ductal adenocarcinoma
Memantine is a potential drug for PDAC therapy. (A). Dose-response curve of memantine in PDAC cells. (B). Cell growth was inhibited in memantine treated PDAC cells, as revealed by CCk8 cell viability assay. (C). Cell migration was inhibited in memantine treated PDAC cells, as revealed by wound healing cell migration assay. (D). Clonogenic ability was inhibited in memantine treated PDAC cells, the cells in the colony formation assay were stained by crystal violet. (E). Level of GRIN2D decreased in memantine treated PDAC cells. (F). p38, MSK, and CREB in p38 MAPK signaling pathway were dephosphorylated after treatment of memantine. Data are from at least three independent experiments. Mean ± SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001